Post-COVID mucormycosis: A retrospective observational study
Introduction: Mucormycosis is a life-threatening fungal infection caused by fungi belonging to the family Mucorales, and the fungus mainly responsible for infection in humans is Rhizopus oryzae. Recently, several cases of coronavirus disease 2019 (COVID-19)-associated mucormycosis are being reported...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Jaypee Brothers Medical Publisher
2022-01-01
|
| Series: | Indian Journal of Respiratory Care |
| Subjects: | |
| Online Access: | http://www.ijrc.in/article.asp?issn=2277-9019;year=2022;volume=11;issue=3;spage=230;epage=233;aulast=Shaik |
| _version_ | 1797696781841072128 |
|---|---|
| author | Nurani Shaik Akhila Bollam Gayathri Konduri Aedula Vinaya Sekhar |
| author_facet | Nurani Shaik Akhila Bollam Gayathri Konduri Aedula Vinaya Sekhar |
| author_sort | Nurani Shaik |
| collection | DOAJ |
| description | Introduction: Mucormycosis is a life-threatening fungal infection caused by fungi belonging to the family Mucorales, and the fungus mainly responsible for infection in humans is Rhizopus oryzae. Recently, several cases of coronavirus disease 2019 (COVID-19)-associated mucormycosis are being reported worldwide. Subjects and Methods: A retrospective observational study was conducted in the emergency department at a tertiary care hospital for 2 months. The primary objectives of this study were to assess the risk factors of post COVID-19 the signs and symptoms, toassess the relationship between steroidal usage and post-COVID-19 mucormycosis evaluating the treatment patterns. Results and Discussion: In the current study, 45 cases were examined. It was found that patients with comorbidities, especially diabetes mellitus, i.e., 80%, have more exposure to post-COVID-19 mucormycosis than any other comorbidity. It is also found that methylprednisolone is the major steroid used, accounting for 43% of the steroids used for the treatment of COVID. The treatment included the usage of lipophilic amphotericin B in 61% of the patients, which is associated with lipophilic posaconazole in 95% of the patients. Conclusion: Post-COVID-19 mucormycosis is a major threat to the individuals affected with COVID-19. The major risk factor is the presence of diabetes mellitus; therefore, proper measures must be undertaken in diabetic patients. Patient develops any symptoms related to the eyes, nose, face, lungs, and skin should seek a medical emergency to avoid chronic complications. |
| first_indexed | 2024-03-12T03:31:06Z |
| format | Article |
| id | doaj.art-aaa7b5781a3345e3aa95236786ac1ea2 |
| institution | Directory Open Access Journal |
| issn | 2277-9019 2321-4899 |
| language | English |
| last_indexed | 2024-03-12T03:31:06Z |
| publishDate | 2022-01-01 |
| publisher | Jaypee Brothers Medical Publisher |
| record_format | Article |
| series | Indian Journal of Respiratory Care |
| spelling | doaj.art-aaa7b5781a3345e3aa95236786ac1ea22023-09-03T13:26:28ZengJaypee Brothers Medical PublisherIndian Journal of Respiratory Care2277-90192321-48992022-01-0111323023310.4103/ijrc.ijrc_26_22Post-COVID mucormycosis: A retrospective observational studyNurani ShaikAkhila BollamGayathri KonduriAedula Vinaya SekharIntroduction: Mucormycosis is a life-threatening fungal infection caused by fungi belonging to the family Mucorales, and the fungus mainly responsible for infection in humans is Rhizopus oryzae. Recently, several cases of coronavirus disease 2019 (COVID-19)-associated mucormycosis are being reported worldwide. Subjects and Methods: A retrospective observational study was conducted in the emergency department at a tertiary care hospital for 2 months. The primary objectives of this study were to assess the risk factors of post COVID-19 the signs and symptoms, toassess the relationship between steroidal usage and post-COVID-19 mucormycosis evaluating the treatment patterns. Results and Discussion: In the current study, 45 cases were examined. It was found that patients with comorbidities, especially diabetes mellitus, i.e., 80%, have more exposure to post-COVID-19 mucormycosis than any other comorbidity. It is also found that methylprednisolone is the major steroid used, accounting for 43% of the steroids used for the treatment of COVID. The treatment included the usage of lipophilic amphotericin B in 61% of the patients, which is associated with lipophilic posaconazole in 95% of the patients. Conclusion: Post-COVID-19 mucormycosis is a major threat to the individuals affected with COVID-19. The major risk factor is the presence of diabetes mellitus; therefore, proper measures must be undertaken in diabetic patients. Patient develops any symptoms related to the eyes, nose, face, lungs, and skin should seek a medical emergency to avoid chronic complications.http://www.ijrc.in/article.asp?issn=2277-9019;year=2022;volume=11;issue=3;spage=230;epage=233;aulast=Shaikamphotericin bcoviddiabetes mellitusposaconazolepostcoronavirus disease 2019 mucormycosis |
| spellingShingle | Nurani Shaik Akhila Bollam Gayathri Konduri Aedula Vinaya Sekhar Post-COVID mucormycosis: A retrospective observational study Indian Journal of Respiratory Care amphotericin b covid diabetes mellitus posaconazole postcoronavirus disease 2019 mucormycosis |
| title | Post-COVID mucormycosis: A retrospective observational study |
| title_full | Post-COVID mucormycosis: A retrospective observational study |
| title_fullStr | Post-COVID mucormycosis: A retrospective observational study |
| title_full_unstemmed | Post-COVID mucormycosis: A retrospective observational study |
| title_short | Post-COVID mucormycosis: A retrospective observational study |
| title_sort | post covid mucormycosis a retrospective observational study |
| topic | amphotericin b covid diabetes mellitus posaconazole postcoronavirus disease 2019 mucormycosis |
| url | http://www.ijrc.in/article.asp?issn=2277-9019;year=2022;volume=11;issue=3;spage=230;epage=233;aulast=Shaik |
| work_keys_str_mv | AT nuranishaik postcovidmucormycosisaretrospectiveobservationalstudy AT akhilabollam postcovidmucormycosisaretrospectiveobservationalstudy AT gayathrikonduri postcovidmucormycosisaretrospectiveobservationalstudy AT aedulavinayasekhar postcovidmucormycosisaretrospectiveobservationalstudy |